Longboard Pharmaceuticals/LBPH

$22.86

1.74%
-
1D1W1MYTD1YMAX

About Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing medicines for neurological diseases. Its pipeline includes LP352 and LP659. LP352 is an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, CDKL5 deficiency disorder, SCN2A-related disorders, among others. LP659 is a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator for inflammatory neurological conditions. LP659 is designed to avoid the negative effects connected to the receptor subtypes 2 and 3, which is associated with serious, off-target cardiac, pulmonary, and cancer-related effects. It also has license to certain compounds including LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, and compounds targeting the 5-HT2A receptor, including nelotanserin.

Ticker

LBPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kevin Lind

Employees

33

Headquarters

La jolla, United States

LBPH Metrics

BasicAdvanced
$760.54M
Market cap
-
P/E ratio
-$2.42
EPS
-
Beta
-
Dividend rate

What the Analysts think about LBPH

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
84.34% upside
High $60.00
Low $30.00
$22.86
Current price
$42.14
Average price target

LBPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-12.9M
-13.42%
Profit margin
0%
-

LBPH Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.87%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.66
-$0.56
-$0.65
-$0.55
-
Expected
-$0.69
-$0.57
-$0.60
-$0.70
-$0.60
Surprise
-4.95%
-2.49%
9.11%
-21.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Longboard Pharmaceuticals stock

Buy or sell Longboard Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing